



MARKET RELEASE

17 November 2017

Noxopharm Limited

TRADING HALT

The securities of Noxopharm Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Tuesday, 21 November 2017 or when the announcement is released to the market.

Security Code: NOX

Dean Litis
PRINCIPAL ADVISER, LISTINGS COMPLIANCE (MELBOURNE)



ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office:

Suite 1 Level 6
50 Queen St
Melbourne VIC 3000
Australia

Operational Office:

Suite 3, Level 4
828 Pacific Highway
Gordon NSW 2072
Australia

Board of Directors

Mr Peter Marks

Chairman
Non-Executive
Director

Dr Graham Kelly

Chief Executive Officer
Managing Director

Dr Ian Dixon

Non-Executive
Director

17 November 2017

Ms Cheng Tang
Adviser
Listings Compliance (Melbourne)
ASX Compliance Pty Limited
Level 4 Rialto North Tower
525 Collins Street
Melbourne VIC 3000

By Email: cheng.tang@asx.com.au

By Email: tradinghaltsmelbourne@asx.com.au

Dear Cheng,

NOXOPHARM LIMITED – TRADING HALT

The Company requests a trading halt effective immediately pending the release of an announcement in relation to public release on 18th November 2017 of clinical trial data from the Company's first-in-human NOX66 clinical study in Georgia. The trading halt is requested until the earlier of the release of an announcement regarding the clinical trial data, or prior to the opening of trading on Tuesday 21 November 2017.

The Company is not aware of any reason why the trading halt should not be granted.

Thank you for your assistance. If you have any questions please contact the Company Secretary, David Franks on (02) 9299 9690.

For and on behalf of the Board,

Yours faithfully,

David Franks
Company Secretary